Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is expected to continue its strong performance with its diverse workforce and successful PayGo program, providing an opportunity for investors. The launch of its Mobi pump and development of a closed-loop algorithm for its pumps also indicate potential for growth. However, potential risks such as competition and supply chain management should be considered. Overall, the company's potential for long-term growth and current undervalued stock make it an attractive investment opportunity.

Bears say

Tandem Diabetes Care is a player in the insulin pump market that, while having an impressive portfolio of pump offerings and demonstrating strong accuracy with its Control IQ feature, is facing challenges. These challenges include slower-than-expected adoption outside of the US, a need for reimbursement in Type 2 patients, and expected future investment for their upcoming pumps. Furthermore, while the company has set ambitious targets, it remains to be seen whether they can achieve them, given the current competitive and regulatory landscape.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.